| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1042763763 |
| P356 | DOI | 10.1038/NG0593-42 |
| P698 | PubMed publication ID | 8099841 |
| P50 | author | Dirk Dittmer | Q71109132 |
| P2093 | author name string | Levine AJ | |
| Moore M | |||
| Pati S | |||
| Chu S | |||
| Teresky AK | |||
| Zambetti G | |||
| Finlay C | |||
| P2860 | cites work | Definition of a consensus binding site for p53 | Q28207794 |
| Oncogenic forms of p53 inhibit p53-regulated gene expression | Q28251120 | ||
| Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas | Q28269089 | ||
| The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation | Q28280958 | ||
| Identification of p53 as a sequence-specific DNA-binding protein | Q28282745 | ||
| p53 mutations in human cancers | Q28302973 | ||
| The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 | Q29547773 | ||
| Suppression of human colorectal carcinoma cell growth by wild-type p53 | Q29618318 | ||
| Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. | Q33740135 | ||
| p53 functions as a cell cycle control protein in osteosarcomas | Q34254691 | ||
| Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein | Q34343950 | ||
| Rearrangement of the p53 gene in human osteogenic sarcomas | Q34360802 | ||
| The p53 proto-oncogene can act as a suppressor of transformation | Q34440370 | ||
| Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells | Q36679234 | ||
| Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex | Q36867104 | ||
| Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species | Q36942353 | ||
| A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs | Q37599465 | ||
| The p53 tumour suppressor gene | Q37751892 | ||
| Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53 | Q38325583 | ||
| Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers | Q38487557 | ||
| A transcriptionally active DNA-binding site for human p53 protein complexes | Q40655196 | ||
| Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element | Q41614914 | ||
| Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. | Q41643433 | ||
| p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts | Q41654913 | ||
| Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein | Q41696617 | ||
| Genetic mechanisms of tumor suppression by the human p53 gene | Q41710706 | ||
| Growth regulation of a cellular tumour antigen, p53, in nontransformed cells | Q42819146 | ||
| Association of human papillomavirus types 16 and 18 E6 proteins with p53. | Q43701619 | ||
| Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53 | Q43927270 | ||
| Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication | Q44703400 | ||
| Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. | Q53548575 | ||
| Participation of p53 cellular tumour antigen in transformation of normal embryonic cells | Q53548581 | ||
| p53 expression and prognosis in gastric carcinoma | Q57416537 | ||
| Overproduction of p53 antigen makes established cells highly tumorigenic | Q59053537 | ||
| Wild-type p53 activates transcription in vitro | Q59054260 | ||
| Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA | Q68087656 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 42-46 | |
| P577 | publication date | 1993-05-01 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Gain of function mutations in p53 | |
| P478 | volume | 4 |
| Q34158824 | 17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells. |
| Q84583331 | 20 years studying p53 functions in genetically engineered mice |
| Q38986437 | A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels. |
| Q28118809 | A common polymorphism acts as an intragenic modifier of mutant p53 behaviour |
| Q74292374 | A mutant P53 can activate apoptosis through a mechanism distinct from those induced by wild type P53 |
| Q33861971 | A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity |
| Q72293593 | A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice |
| Q40427572 | A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug |
| Q51660356 | A naturally occurring p73 mutation in a p73-p53 double-mutant lung cancer cell line encodes p73 alpha protein with a dominant-negative function. |
| Q27937248 | A nuclear FK506-binding protein is a histone chaperone regulating rDNA silencing |
| Q92168046 | A quantitative model to predict pathogenicity of missense variants in the TP53 gene |
| Q38847062 | AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation |
| Q38851714 | APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma |
| Q34888948 | Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts |
| Q35088549 | Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells |
| Q35161695 | Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer |
| Q40626617 | Acquisition of anoikis resistance in human osteosarcoma cells |
| Q39575066 | Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain |
| Q40037740 | Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. |
| Q40860429 | Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma |
| Q38358499 | Adenovirus E1A proteins inhibit activation of transcription by p53. |
| Q39578554 | Adenovirus type 12-induced fragility of the human RNU2 locus requires p53 function. |
| Q30426125 | Advances in the genetics of glioblastoma: are we reaching critical mass? |
| Q34638529 | Allele-specific p53 mutant reactivation |
| Q34195780 | An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele |
| Q40198133 | An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations |
| Q36065506 | An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control |
| Q41581367 | An unexpected spectrum of p53 mutations from squamous cell carcinomas in psoriasis patients treated with PUVA. |
| Q54163191 | Analysis of MDR1 and MDR3 multidrug resistance gene expression and amplification in consecutive samples in patients with acute leukaemias. |
| Q34251029 | Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas |
| Q40792701 | Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. |
| Q51033341 | Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. |
| Q72161523 | Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations |
| Q78192930 | Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant |
| Q28611432 | Apoptosis, cancer and the p53 tumour suppressor gene |
| Q28541801 | Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase |
| Q34570100 | Assessing TP53 status in human tumours to evaluate clinical outcome |
| Q46684018 | Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy |
| Q64253267 | Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival |
| Q34280860 | BRCA1 and prostate cancer |
| Q30175418 | Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. |
| Q41141483 | Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions |
| Q41185267 | Breast cancer in African American women: epidemiology and tumor biology |
| Q48022098 | CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA. |
| Q34580489 | Cancer chemoresistance: the relationship between p53 and multidrug transporters |
| Q27692076 | Caught in the cross fire: p53 in inflammation. |
| Q51623974 | Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53(R172H). |
| Q40540649 | Cell type-specific regulation of calmodulin 2 expression by mutant p53. |
| Q36078151 | Challenges in identifying cancer genes by analysis of exome sequencing data. |
| Q92153177 | Characterization of p53 Family Homologs in Evolutionary Remote Branches of Holozoa |
| Q40476542 | Clinical applications of the p53 tumor suppressor gene |
| Q35735278 | Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. |
| Q91526471 | Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers |
| Q28143345 | Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants |
| Q60950807 | Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations |
| Q92455292 | Common genetic variants in the TP53 pathway and their impact on cancer |
| Q71116149 | Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis |
| Q34760892 | Comparison of modules of wild type and mutant Huntingtin and TP53 protein interaction networks: implications in biological processes and functions |
| Q74610152 | Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma |
| Q40909124 | Complete loss of wild-type TP53 in a nontransformed human epithelial cell line is preceded by a phase during which a heterozygous TP53 mutant effectively outgrows the homozygous wild-type cells |
| Q46864790 | Complex functions of mutant p53 alleles from human prostate cancer |
| Q46575531 | Constitutional p53 mutations associated with brain tumors in young adults |
| Q36574046 | Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression |
| Q47238975 | Control of Nucleotide Metabolism Enables Mutant p53's Oncogenic Gain-of-Function Activity |
| Q73180055 | Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxic tumor-inhibitory effect of p53 loss in transgenic mouse epidermis |
| Q73510884 | Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis |
| Q27730393 | Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms |
| Q24309263 | Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression |
| Q34499162 | DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53 |
| Q47725050 | DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications |
| Q44165063 | DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. |
| Q33790804 | DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function |
| Q34081815 | Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation |
| Q34117482 | Development and translational imaging of a TP53 porcine tumorigenesis model |
| Q34277292 | Diagnostic and prognostic tumor markers in the gastrointestinal tract. |
| Q38008448 | Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. |
| Q36640204 | Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells |
| Q31047557 | Differential role of PKC-induced c-Jun in HTLV-1 LTR activation by 12-O-tetradecanoylphorbol-13-acetate in different human T-cell lines |
| Q40017199 | Discrimination of DNA Binding Sites by Mutant p53 Proteins |
| Q35078774 | Disrupting TP53 in mouse models of human cancers |
| Q40202977 | Dissecting the senescence-like program in tumor cells activated by Ras signaling |
| Q39744147 | Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas |
| Q42072409 | Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2. |
| Q62057894 | Diverse and cancer type‑specific roles of the p53 R248Q gain‑of‑function mutation in cancer migration and invasiveness |
| Q42035568 | Does control of mutant p53 by Mdm2 complicate cancer therapy? |
| Q71820075 | Dominant‐negative p53 can restore tumorigenicity of L‐929 cells in immunocompetent mice |
| Q40791236 | Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. |
| Q79300657 | Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma |
| Q90911426 | EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins |
| Q28275900 | EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I |
| Q39576374 | Ectopic expression of cdc2/cdc28 kinase subunit Homo sapiens 1 uncouples cyclin B metabolism from the mitotic spindle cell cycle checkpoint |
| Q36295147 | Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene |
| Q36617550 | Elderly Japanese women with cervical carcinoma show higher proportions of both intermediate-risk human papillomavirus types and p53 mutations |
| Q37426890 | Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. |
| Q36615676 | Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53. |
| Q37367149 | Embryonic stem cells shed new light on the developmental roles of p53. |
| Q28077156 | Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness |
| Q60907794 | Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53 |
| Q55284787 | Establishment of cell lines with high- and low-metastatic potential from PC-14 human lung adenocarcinoma. |
| Q40411164 | Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation |
| Q35251779 | Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. |
| Q41762183 | Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. |
| Q53356436 | Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development. |
| Q35312427 | Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells |
| Q37305086 | Formal modeling and analysis of the hexosamine biosynthetic pathway: role of O-linked N-acetylglucosamine transferase in oncogenesis and cancer progression |
| Q40859486 | Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations? |
| Q41617058 | Foulds' dangerous idea revisited: the multistep development of tumors 40 years later. |
| Q34164614 | From p63 to p53 across p73. |
| Q40949902 | Functional analyses of a unique p53 germline mutant (Y236delta) associated with a familial brain tumor syndrome |
| Q24301892 | Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation |
| Q89805344 | Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis |
| Q39467174 | Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. |
| Q91710103 | Gain-of-function mutant p53: history and speculation |
| Q35839280 | Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness |
| Q42795736 | Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms |
| Q38830254 | Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells. |
| Q45887190 | Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. |
| Q36512100 | Genetic and functional analysis of a Li Fraumeni syndrome family in China |
| Q42936703 | Genetic modeling of Li-Fraumeni syndrome in zebrafish |
| Q34438119 | Genetic predisposition to cancer and familial cancer syndromes |
| Q36982414 | Genetically engineered mouse models for skin research: taking the next step |
| Q36493335 | Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management. |
| Q34130332 | Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia |
| Q33905119 | Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk |
| Q34305486 | Ginsenoside Rg3 Inhibits Constitutive Activation of NF-κB Signaling in Human Breast Cancer (MDA-MB-231) Cells: ERK and Akt as Potential Upstream Targets |
| Q24308421 | Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53 |
| Q39214706 | HDAC inhibitor DWP0016 activates p53 transcription and acetylation to inhibit cell growth in U251 glioblastoma cells |
| Q35101216 | Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3 |
| Q33836415 | Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner |
| Q40755915 | Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants |
| Q35673678 | High metastatic potential in mice inheriting a targeted p53 missense mutation |
| Q53885409 | Higher incidence of p53 mutation in cervical carcinomas with intermediate-risk HPV infection. |
| Q36667622 | Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle |
| Q98177150 | Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis |
| Q46914766 | Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells |
| Q35051410 | Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population |
| Q73877057 | Identification of a novel transcriptional regulatory element common to the p53 and interferon regulatory factor 1 genes |
| Q38176221 | Illuminating p53 function in cancer with genetically engineered mouse models |
| Q34117301 | Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. |
| Q43735772 | Immunohistochemical detection of p53 tumor suppressor gene protein in canine epithelial colorectal tumors |
| Q42419195 | Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death |
| Q64380702 | Induction of cell proliferation arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene |
| Q37068656 | Induction of genetic instability by gain-of-function p53 cancer mutants |
| Q33521710 | Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. |
| Q37230210 | Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts |
| Q28212970 | Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization |
| Q34462553 | Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53. |
| Q43831424 | Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. |
| Q28345092 | Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis |
| Q34990640 | Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation |
| Q27009209 | Lessons learned from next-generation sequencing in head and neck cancer |
| Q36080648 | Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. |
| Q40287215 | Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo |
| Q42520917 | Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice |
| Q44084966 | Lung-specific expression of dominant-negative mutant p53 in transgenic mice increases spontaneous and benzo(a)pyrene-induced lung cancer |
| Q53385488 | Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. |
| Q28137943 | MBP1: a novel mutant p53-specific protein partner with oncogenic properties |
| Q35895678 | MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection |
| Q33922100 | MDM2 oligomers: antagonizers of the guardian of the genome |
| Q53409324 | MDM2 overexpression with alteration of the p53 protein and gene status in oral carcinogenesis. |
| Q40667913 | Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function |
| Q35965859 | MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function |
| Q36250209 | Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group |
| Q40982606 | Mitogen-activated protein kinase is involved in the degradation of p53 protein in the bryostatin-1-induced differentiation of the acute promyelocytic leukemia NB4 cell line |
| Q53438921 | Modulation of p53 expression in cultured colonic adenoma cell lines by the naturally occurring lumenal factors butyrate and deoxycholate. |
| Q92445781 | Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy |
| Q92009380 | Molecular changes in solitary fibrous tumor progression |
| Q26822717 | Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date |
| Q33533997 | Molecular epidemiology of human cancer |
| Q33643298 | Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer |
| Q46664230 | Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis? |
| Q40620907 | Molecular mechanisms of radiation oncogenesis |
| Q36066191 | Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway |
| Q35116669 | Mouse models with modified p53 sequences to study cancer and ageing. |
| Q77463323 | Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1 |
| Q58736829 | Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma |
| Q37402942 | Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. |
| Q30354662 | Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. |
| Q26765746 | Mutant p53 and ETS2, a Tale of Reciprocity |
| Q24681272 | Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II |
| Q49791721 | Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α. |
| Q40788757 | Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. |
| Q33791759 | Mutant p53 disrupts the stress MAPK activation circuit induced by ASK1-dependent stabilization of Daxx |
| Q34292432 | Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes |
| Q38204111 | Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks |
| Q77932308 | Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy |
| Q46709821 | Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression |
| Q73876727 | Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q39229004 | Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy |
| Q40265316 | Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. |
| Q64892305 | Mutant p53 in cancer therapy-the barrier or the path. |
| Q38197826 | Mutant p53 in cancer: new functions and therapeutic opportunities |
| Q24337116 | Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion |
| Q44573111 | Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase |
| Q37424034 | Mutant p53 mediates survival of breast cancer cells |
| Q36292196 | Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals |
| Q36661775 | Mutant p53 proteins: between loss and gain of function |
| Q39421527 | Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome |
| Q89944650 | Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells |
| Q36812554 | Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression |
| Q26776020 | Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer |
| Q26770576 | Mutant p53: One, No One, and One Hundred Thousand |
| Q36777355 | Mutant p53: an oncogenic transcription factor |
| Q53422686 | Mutant p53: epigenetic mutator of the T-cell receptor via induction of methylation. |
| Q80078484 | Mutant p53: from guardian to fallen angel? |
| Q33737277 | Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators |
| Q36070574 | Mutant p53: one name, many proteins |
| Q40435601 | Mutation and Expression of TP53 in Malignant Melanomas |
| Q37629482 | Mutation of the endogenous p53 gene in cells transformed by HPV-16 E7 and EJ c-ras confers a growth advantage involving an autocrine mechanism |
| Q25257243 | Mutational hotspots in the TP53 gene and, possibly, other tumor suppressors evolve by positive selection |
| Q35892778 | Mutations and altered expression of p16INK4 in human cancer. |
| Q92890190 | Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer |
| Q74255888 | Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue |
| Q36137812 | N-methylpurine DNA glycosylase inhibits p53-mediated cell cycle arrest and coordinates with p53 to determine sensitivity to alkylating agents |
| Q41585790 | NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity |
| Q39007820 | Neomorphic mutations create therapeutic challenges in cancer. |
| Q43123230 | Not all p53 gain-of-function mutants are created equal |
| Q28208559 | Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil |
| Q36065105 | Nucleolar GTP-binding Protein-1 (NGP-1) Promotes G1 to S Phase Transition by Activating Cyclin-dependent Kinase Inhibitor p21 Cip1/Waf1. |
| Q26749382 | Oncogenic Intra-p53 Family Member Interactions in Human Cancers |
| Q38846785 | Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation |
| Q37394521 | One billion years of p53/p63/p73 evolution |
| Q31121056 | Overexpression of RBBP6, alone or combined with mutant TP53, is predictive of poor prognosis in colon cancer |
| Q35793303 | Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53 |
| Q38045766 | Overexpression of p53 protein in human tumors |
| Q55111247 | P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. |
| Q28611435 | P53, cell cycle control and apoptosis: Implications for cancer |
| Q30416701 | PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations |
| Q93355372 | Patterns of mutations in TP53 mutated AML |
| Q38948352 | Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review |
| Q92914764 | Pharmacological targeting of mutant p53 |
| Q58073315 | Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73 |
| Q38291171 | Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. |
| Q73400368 | Polyamine-depletion induces p27Kip1 and enhances dexamethasone-induced G1 arrest and apoptosis in human T lymphoblastic leukemia cells |
| Q36527456 | Posttranslational phosphorylation of mutant p53 protein in tumor development |
| Q43806353 | Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level |
| Q26824536 | Predictive biomarkers in precision medicine and drug development against lung cancer |
| Q93001945 | Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma |
| Q36135501 | Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas |
| Q74355214 | RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome |
| Q40381752 | Radiation response and cell cycle regulation of p53 rescued malignant keratinocytes |
| Q36082825 | Ranking novel cancer driving synthetic lethal gene pairs using TCGA data |
| Q37294298 | Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. |
| Q30977773 | Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations |
| Q55474891 | Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. |
| Q24655012 | Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene |
| Q90706140 | Regulators of Oncogenic Mutant TP53 Gain of Function |
| Q33927506 | Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells |
| Q40011883 | Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants |
| Q73446293 | Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53 |
| Q42807704 | Retrovirus-mediated p53 gene therapy |
| Q39173336 | Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor |
| Q38161342 | Role of p53 in Cell Death and Human Cancers |
| Q41515342 | Role of p53 in apoptosis. |
| Q39159055 | Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells |
| Q33233542 | Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis |
| Q38901160 | Silencing of ETS1 reverses adriamycin resistance in MCF-7/ADR cells via downregulation of MDR1. |
| Q39876425 | Simian virus 40 small t antigen activates the carboxyl-terminal transforming p53-binding domain of large T antigen. |
| Q34674371 | Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells |
| Q27027835 | Small molecule compounds targeting the p53 pathway: are we finally making progress? |
| Q33898768 | Soft tissue sarcomas and p53 mutations |
| Q57263912 | Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection |
| Q36796242 | Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing |
| Q40040456 | Stabilization of the tumor suppressor p53 during cellular transformation by simian virus 40: influence of viral and cellular factors and biological consequences |
| Q36326004 | Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells |
| Q36941044 | Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. |
| Q34156507 | Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. |
| Q38180665 | TP53 mutants in the tower of babel of cancer progression |
| Q38507513 | TP53: an oncogene in disguise. |
| Q33638172 | Targeting p53 as a general tumor antigen |
| Q91643844 | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors |
| Q41328186 | Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. |
| Q40722479 | The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. |
| Q36134953 | The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene |
| Q24309068 | The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage |
| Q43718785 | The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis |
| Q26772237 | The Contrived Mutant p53 Oncogene - Beyond Loss of Functions |
| Q42323049 | The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants |
| Q38184520 | The Mdm network and its regulation of p53 activities: a rheostat of cancer risk |
| Q35973393 | The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. |
| Q59526203 | The UMD TP53 database and website: update and revisions |
| Q40976806 | The adenovirus E4orf6 protein contributes to malignant transformation by antagonizing E1A-induced accumulation of the tumor suppressor protein p53. |
| Q40039307 | The amino-terminal functions of the simian virus 40 large T antigen are required to overcome wild-type p53-mediated growth arrest of cells. |
| Q34519833 | The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes |
| Q34903861 | The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. |
| Q37225303 | The consequence of oncomorphic TP53 mutations in ovarian cancer |
| Q37115437 | The dark side of a tumor suppressor: anti-apoptotic p53. |
| Q44461256 | The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype |
| Q72293557 | The dominating effect of mutant p53 |
| Q34402080 | The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth |
| Q33593937 | The emerging p53 gene family |
| Q26742058 | The expanding regulatory universe of p53 in gastrointestinal cancer |
| Q36651009 | The gain of function of p53 cancer mutant in promoting mammary tumorigenesis |
| Q74523161 | The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers |
| Q98164574 | The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic |
| Q33888765 | The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis |
| Q40969930 | The human p53 gene mutated at position 249 per se is not sufficient to immortalize human liver cells |
| Q36649149 | The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss |
| Q35961417 | The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation. |
| Q40041349 | The kinetics of simian virus 40-induced progression of quiescent cells into S phase depend on four independent functions of large T antigen |
| Q92701432 | The many faces of p53: something for everyone |
| Q41331238 | The molecular epidemiology of p53 gene mutations in human breast cancer |
| Q38203467 | The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact |
| Q57162865 | The p53 Pathway in Glioblastoma |
| Q40961528 | The p53 gene and its role in human brain tumors. |
| Q33807839 | The p53 gene family |
| Q34187832 | The p53 tumour suppressor protein |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q24533291 | The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression |
| Q34153014 | The role of mutant p53 in human cancer |
| Q36401780 | The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope |
| Q40925430 | The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype |
| Q73171130 | The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association |
| Q42290127 | The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer |
| Q37081504 | The use of p53 as a tool for human cancer therapy |
| Q47742599 | Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others |
| Q36376876 | Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. |
| Q38334166 | Transactivation of the EGR1 gene contributes to mutant p53 gain of function |
| Q36671026 | Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. |
| Q36777349 | Transcription regulation by mutant p53. |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q35567283 | Transcriptional regulation of ABC drug transporters |
| Q40488280 | Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation |
| Q34194706 | Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape |
| Q29617436 | Tumor spectrum analysis in p53-mutant mice |
| Q33638362 | Tumor suppressor genes and breast cancer |
| Q41625163 | Tumor suppressor genes and human cancer |
| Q27000754 | Tumor suppressor p53 and its gain-of-function mutants in cancer |
| Q34314048 | Tumor suppressor p53 mutations and breast cancer: a critical analysis |
| Q28208109 | Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction |
| Q40852695 | Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation |
| Q39614332 | Tumor-derived p53 mutants induce NF-kappaB2 gene expression |
| Q40568020 | Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. |
| Q33807787 | Twenty years of p53 research: structural and functional aspects of the p53 protein |
| Q35025009 | Unraveling the molecular genetics of head and neck cancer through genome-wide approaches |
| Q38205099 | Unravelling mechanisms of p53-mediated tumour suppression |
| Q34110697 | Update on human polyomaviruses and cancer |
| Q35086367 | Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance |
| Q59640226 | Vaccination anti-p53 |
| Q37087404 | Versatile functions of p53 protein in multicellular organisms |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
| Q47445549 | Why are there hotspot mutations in the TP53 gene in human cancers? |
| Q56029437 | Wild Type p53 Stimulates Expression from the Human Multidrug Resistance Promoter in a p53-negative Cell Line |
| Q38288588 | Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter |
| Q42456543 | Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin |
| Q40020132 | YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity |
| Q55471290 | Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics. |
| Q36438552 | beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells |
| Q33492556 | cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer |
| Q34832663 | microRNAs: short non-coding bullets of gain of function mutant p53 proteins |
| Q36568624 | neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice |
| Q34313764 | p53 Research: the past thirty years and the next thirty years. |
| Q52192096 | p53 activity is essential for normal development in Xenopus. |
| Q36777320 | p53 alterations in human cancer: more questions than answers. |
| Q45889835 | p53 and brain tumors: from gene mutations to gene therapy |
| Q38740922 | p53 and its mutants on the slippery road from stemness to carcinogenesis |
| Q55239676 | p53 antisense oligonucleotide inhibits growth of human colon tumor and normal cell lines. |
| Q37604767 | p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. |
| Q92083193 | p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death |
| Q48144021 | p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome |
| Q40106083 | p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells |
| Q38852853 | p53 immunohistochemical expression of Egyptian cervical carcinoma |
| Q73089635 | p53 is a rate-limiting factor in the repair of higher-order DNA structure |
| Q36622414 | p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas |
| Q24336880 | p53 modulation of TFIIH–associated nucleotide excision repair activity |
| Q91895544 | p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition |
| Q35119547 | p53 mutations and resistance to chemotherapy: A stab in the back for p73 |
| Q38069463 | p53 mutations in cancer |
| Q36294933 | p53 protein expression in nephroblastomas: a predictor of poor prognosis |
| Q48724136 | p53 protein in pediatric malignant astrocytomas: a study of 21 patients |
| Q44040215 | p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. |
| Q53417430 | p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. |
| Q37239773 | p53 signaling is involved in leptin-induced growth of hepatic and breast cancer cells |
| Q34393678 | p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. |
| Q34636742 | p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment |
| Q89783061 | p53's Extended Reach: The Mutant p53 Secretome |
| Q41884266 | p53, chemokines, and squamous cell carcinoma |
| Q34515770 | p53, p63 and p73--solos, alliances and feuds among family members |
| Q27860990 | p53, the cellular gatekeeper for growth and division |
| Q52645040 | p53-Mediated Molecular Control of Autophagy in Tumor Cells. |
| Q36605767 | p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents |
| Q91672818 | p53: Multiple Facets of a Rubik's Cube |
| Q53556002 | p53: a two-faced cancer gene. |
| Q45888635 | p53: balancing tumour suppression and implications for the clinic |
| Q91771321 | p53: not just a tumor suppressor |
| Q42539520 | p63 Gene mutations in eec syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation. |
| Q40896738 | p73 transcriptional activity increases upon cooperation between its spliced forms |
| Q33774367 | ω-3 free fatty acids and all-trans retinoic acid synergistically induce growth inhibition of three subtypes of breast cancer cell lines |
Search more.